International audienceNatural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond...
Central nervous system acute lymphoblastic leukemia (CNS-ALL) is a major clinical problem. Prophylac...
International audienceChemotherapies allow complete remission in more than 50 % of patients with acu...
International audienceNK cells are defective in acute myeloid leukemia (AML) at diagnosis. Here, we ...
International audienceNatural Killer (NK) cells are potent anti-leukemic immune effectors. However, ...
Despite recent progress in the therapeutic approach of malignant hemopathies, their prognoses remain...
Les cellules Natural Killer (NK) sont des effecteurs immuns anti-leucémiques. Toutefois, elles sont ...
Acute myeloid leukemia (AML) cells induce, in vitro, NK cell abnormalities (NKCAs) including apoptos...
The majority of patients with acute myeloid leukemia will relapse, and older patients often fail to ...
Abstract Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers in...
Central nervous system acute lymphoblastic leukemia (CNS-ALL) is a major clinical problem. Prophylac...
International audienceChemotherapies allow complete remission in more than 50 % of patients with acu...
International audienceNK cells are defective in acute myeloid leukemia (AML) at diagnosis. Here, we ...
International audienceNatural Killer (NK) cells are potent anti-leukemic immune effectors. However, ...
Despite recent progress in the therapeutic approach of malignant hemopathies, their prognoses remain...
Les cellules Natural Killer (NK) sont des effecteurs immuns anti-leucémiques. Toutefois, elles sont ...
Acute myeloid leukemia (AML) cells induce, in vitro, NK cell abnormalities (NKCAs) including apoptos...
The majority of patients with acute myeloid leukemia will relapse, and older patients often fail to ...
Abstract Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers in...
Central nervous system acute lymphoblastic leukemia (CNS-ALL) is a major clinical problem. Prophylac...
International audienceChemotherapies allow complete remission in more than 50 % of patients with acu...
International audienceNK cells are defective in acute myeloid leukemia (AML) at diagnosis. Here, we ...